508. Nirmatrelvir/ritonavir use among patients with cancer and COVID-19 is associated with improved clinical outcomes: Single-institution case-control study

BACKGROUND: Patients with cancer are at increased risk for severe and lethal COVID-19, compared to the general population. Currently, with no anti-spike monoclonal antibodies available against circulating variants of SARS-CoV-2, the logistic limitations of outpatient remdesivir infusions, and lack o...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvanitis, Panos, Vieira, Kendra, Warner, Jeremy L, Farmakiotis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678017/
http://dx.doi.org/10.1093/ofid/ofad500.577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678017/
http://dx.doi.org/10.1093/ofid/ofad500.577

Ejemplares similares